Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695780 | 0.86 | KCNH2 (0.55) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6695310 | 0.85 | KCNH2 (0.49) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6692192 | 0.85 | KCNH2 (0.50) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6702138 | 0.85 | F2 (0.59) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6694391 | 0.84 | KCNH2 (0.49) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6695875 | 0.84 | POLA1 (0.50) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6690883 | 0.81 | KCNH2 (0.47) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6696488 | 0.80 | ALDH1A1 (0.49) | POLA1KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL6695586 | 0.80 | KCNH2 (0.49) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6694728 | 0.80 | KCNH2 (0.49) | POLA1KCNH2MEN1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| EP-1265873-B1 | 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2003-10-15 | — | — | EP | claimed |
| US-6624160-B2 | Especially infections of herpes simplex virus type 1, 2, 6, 7, or 8, varicella zoster virus, human cytomegalovirus or epstein-Barr virus; enzyme inhibitors of virus DNA polymerase | PHARMACIA & UPJOHN CO. | 2003-09-23 | — | — | US | claimed |
| EP-1265873-A2 | 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020045619-A1 | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-18 | — | — | US | claimed |
| WO-2001070706-A2 | 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| EP-1265873-B1 | 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6624160-B2 | Especially infections of herpes simplex virus type 1, 2, 6, 7, or 8, varicella zoster virus, human cytomegalovirus or epstein-Barr virus; enzyme inhibitors of virus DNA polymerase | PHARMACIA & UPJOHN CO. | 2003-09-23 | — | — | US | disclosed |
| US-20020045619-A1 | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045619-A1 | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, EIF2AK2 | POLA1 219/4885KCNH2 2120/4885MEN1 1342/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | POLA1 2850/4885KCNH2 4046/4885MEN1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.